Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status

Abstract Background/Aim For patients treated with osimertinib as first-line therapy, there have been no studies comparing both progression-free survival (PFS) and overall survival (OS) according to performance status (PS). Furthermore, no studies have examined differences in baseline genetic abnorma...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Yoshihiko Taniguchi, Akihiro Tamiya, Mitsuo Osuga, Daijiro Harada, Shun-ichi Isa, Keiichi Nakamura, Yasuyuki Mizumori, Tsutomu Shinohara, Hidetoshi Yanai, Katsumi Nakatomi, Masahide Oki, Masahide Mori, Tomohito Kuwako, Koji Yamazaki, Atsuhisa Tamura, Masahiko Ando, Yasuhiro Koh
Format:	Artigo
Język:	Inglês
Wydane:	BMC 2024-08-01
Seria:	BMC Pulmonary Medicine
Hasła przedmiotowe:	EGFR mutations Osimertinib Overall survival Performance status Progression-free survival
Dostęp online:	https://doi.org/10.1186/s12890-024-03212-5
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!